CD47|SIRPα SUMMIT
THE CD47/SIRPa SUMMIT HAS BEEN POSTPONED TO NOVEMBER 4-5th, FOLLOWING THE ESCALATION OF THE COVID-19 CORONAVIRUS OUTBREAK. IF YOU HAVE ANY QUERIES WITH REGARDS TO THIS EVENT, PLEASE GET IN TOUCH WITH US VIA THE CONTACT US PAGE.

CD47|SIRPα SUMMIT

November 4-5 | Boston, MA.

Targeting The Leading “Don’t Eat Me” Signal

Registration Agenda

2020 Partners

Knowledge Partner
Knowledge Partner

For drug discovery and development scientists, Eurofins DiscoverX is the trusted product solutions provider that can accelerate your programs with confidence with qualified reagents, cell lines, and assays ready to run today.

Eurofins DiscoverX develops and manufactures cutting edge assays, stable cell lines, membrane preps, enzymes, and reagents for drug discovery and development from our 3 R&D and manufacturing centers of excellence – San Francisco Bay Area California; St. Louis, Missouri; and Poitiers, France.

Rediscover how Eurofins DiscoverX expertise and trusted products accelerate your programs and enable you to take your drug to the next phase with confidence. With end-to-end support every step of the way for your programs from Discovery to QC lot release.

KEY FEATURES
EXCLUSIVELY DEDICATED

After the great success of the 1st annual CD47|Sirpα summit back in April, this meeting is still the only event solely dedicated to exploring the CD47/SIRPα axis.

PIONEERING SPEAKER FACULTY

Hear from and meet the gurus of the field and the most exciting newcomers from biotech, academia and pharma.

CRUCIAL DISCUSSIONS

Differing approaches to targeting the CD47/SIRPα axis, key fundamental biology, combination therapies and more will be dissected through interactive presentations, panel discussions and open Q&A.

SENIOR-LEVEL NETWORKING

Meet with industry influencers and decision-makers in this intimate and high-quality setting to generate genuinely impactful connections and takeaways.

CURATED LEARNING JOURNEY

Travel from the known to the unknown and the simple to the complex through a carefully constructed end-to-end learning experience.

2 IMPACTFUL DAYS

This space is advancing, that’s why this year, the CD47|SIRPα Summit has been extended to two jam-packed days to allow enough time for crucial topics to be discussed in detail.

WITH VERY PROMISING RESULTS FROM THE FIRST CLINICAL STUDIES, THE DEDICATED CD47/SIRPα SUMMIT IS PERFECTLY TIMED. THIS EVENT PROVIDES THE OPPORTUNITY FOR THOSE WHO HAVE PIONEERED THE SPACE AND ALSO THE NEWCOMERS OF THE INDUSTRY TO GET TOGETHER AND LEARN MORE ABOUT THIS DYNAMIC AND EXCITING FIELD.

Timo Van Den Berg, Professor of Immunotherapy, Head Department of Blood Cell Research, Sanquin Research, Amsterdam University Medical Center

THE CD47/SIRPα SUMMIT IS A VALUABLE OPPORTUNITY TO SHARE OUR LEARNINGS AND EXPLORE IMPORTANT QUESTIONS ABOUT TARGETING THE MYELOID CHECKPOINT PATHWAY FOR THE TREATMENT OF CANCER.

Hong Wan, Chief Scientific Officer, ALX Oncology

Speakers

Kipp Weiskopf
Kipp Weiskopf
Whitehead Fellow
Whitehead Institute
Kipp Weiskopf
Whitehead Fellow
Whitehead Institute

Kipp Weiskopf, M.D., Ph.D is a clinical fellow in Hematology and Oncology at the Dana-Farber Cancer Institute in Boston, MA. He earned his medical and graduate degrees at Stanford University in the Medical Scientist Training Program. As a member of the laboratory of Irving Weissman, M.D., he characterized the CD47/SIRPα interaction as a myeloid immune checkpoint. He developed engineered SIRPα variants that augment macrophage phagocytosis of cancer and serve as universal enhancers of tumor-opsonizing therapeutic antibodies. He further demonstrated that CD47-blocking therapies can be effective for small cell lung cancer and that CD47-blocking therapies can permit bone marrow transplantation without chemotherapy or radiation. Weiskopf has also developed anti-SIRPα antibodies and showed they enhance phagocytosis in response to tumor-opsonizing antibodies. He further demonstrated that the CD47/SIRPa axis is conserved across evolutionary barriers. More recently, he identified a role for MHC class I molecules as regulators of macrophage activation. Weiskopf is a co-Founder of ALX Oncology, and technology he developed has been licensed to Forty Seven, Inc.

Weiskopf completed his medical training in Internal Medicine Residency Program at Brigham and Women’s Hospital in Boston. He has been awarded the Winston Churchill Scholarship, an NCI Ruth L. Kirschstein NRSA Fellowship, the Harold M. Weintraub Graduate Student Award, the Joanna M. Nicolay Melanoma Foundation Research Scholar Award, and first place in the 2013 Collegiate Inventors Competition. He delivered the PEGS 2018 Young Scientist Keynote address. His ongoing research interests lie in identifying novel myeloid immune checkpoints that regulate macrophage activation within the tumor microenvironment.

Jaume Pons
Jaume Pons
President & CEO
ALX Oncology
Jaume Pons
President & CEO
ALX Oncology

Dr. Pons previously served as Chief Scientific Officer and site head of Rinat (Pfizer), where he was responsible for portfolio delivery from idea to clinical development. He implemented the vision of a company unit following biology across therapeutic areas while generating advanced antibody technologies and turned Rinat into the center of cancer immunology for Pfizer. Dr. Pons is an inventor of fremanezumab, which was approved by the FDA in 2018, as well as two other antibodies in late-stage clinical development and has advanced nine additional antibodies into human trials in multiple therapeutic areas. As Senior Vice President of R&D, he was a member of Pfizer’s World R&D Leadership Team. Before Pfizer, Dr. Pons created and led Rinat’s protein engineering group and was a scientist at Chiron. Dr. Pons earned his Ph.D. in molecular and cell biology at the Institute on Fundamental Biology, Barcelona, and an M.S. in biotechnology and B.S. in biochemistry from Autonoma University of Barcelona. He conducted his postdoctoral studies in antibody engineering at the University of California, Berkeley.

Timo Van Den Berg
Timo Van Den Berg
Professor of Immunotherapy, Head Department of Blood Cell Research
Sanquin Research, Amsterdam University Medical Center
Timo Van Den Berg
Professor of Immunotherapy, Head Department of Blood Cell Research
Sanquin Research, Amsterdam University Medical Center

Timo Van Den Berg’s group was among the pioneering groups to describe cloning of the inhibitory receptor SIRPα and the first to describe its myeloid-restricted expression. His group have since been studying the physiological functions of CD47-SIRPα interactions and co-discovered, more or less together with the Weissman group at Stanford University, that its acts as an immune checkpoint in the context of antibody therapy in cancer. The method of interfering with the CD47-SIRPα innate immune checkpoint in combination with cancer-targeting monoclonal antibodies in cancer was successfully patented (WO2009/131453), and this was licensed to Synthon Biopharmaceuticals BV who they are collaborating with to develop agents targeting the CD47-SIRPα interaction.

Michal Caspi Tal
Michal Caspi Tal
Instructor and Team Lead
Stanford University
Michal Caspi Tal
Instructor and Team Lead
Stanford University

Dr. Michal (Mikki) Tal is an instructor at Stanford University School of Medicine studying host-pathogen interactions with a focus on immune clearance and diversity of immune responses to tick-borne diseases. Michal received her PhD at Yale University in Immunobiology under the mentorship of Akiko Iwasaki. Dr Tal then did her postdoctoral training in the laboratory of Irving Weissman at Stanford where she is currently an instructor leading the infectious disease team and studying the immumodulatory mechanisms by which the CD47-SIRPa axis impacts immune clearance of infectious disease.  Dr. Tal received the Yale Gershon Fellowship, NIH NIAID F30 and F31 pre and postdoctoral fellowships, was selected to give the inaugural Janeway early career lecture at Yale University, and awarded the Emerging Leader Award from Bay Area Lyme Foundation.

Nicolas Poirier
Nicolas Poirier
Chief Scientific Officer
OSE Immunotherapeutics
Nicolas Poirier
Chief Scientific Officer
OSE Immunotherapeutics

Nicolas Poirier earned his Ph.D. in Immunology at the European Center of Transplantation Sciences and Immunotherapy (CESTI) with guidance from immunotherapeutic-Transplant pioneer. He worked on the preclinical evaluation of novel therapeutic strategies modulating costimulation, immune checkpoint or complement pathways in preclinical models of transplantation and chronic inflammation. He received the awards “Prix de la Recherche Universitaire” by the French journal Le Monde and “New Key Opinion Leader” by the International Society of Transplantation. In 2009, he joined Effimune, a French biotechnology company specialized in immune regulation, where he led R&D programs for 7 years. Upon the merger of Effimune with OSE pharma in 2016, he was appointed Chief Scientific Officer of OSE Immunotherapeutics, a leading biotechnology company in the field of immune activation and regulation with clinical applications in immuno-oncology, autoimmune diseases and transplantation. As CSO, he supported the company’s growth and his R&D team is interested in identification, evaluation and development of innovative immunotherapies to establish, break, regulate or reinforce immune regulation and activation.

Siddhartha Mitra
Siddhartha Mitra
Assistant Professor
University of Colorado
Siddhartha Mitra
Assistant Professor
University of Colorado

Dr. Mitra is currently an Assistant Professor of Pediatrics at the University of Colorado School of Medicine and the Children’s Hospital Colorado in the Division of Hematology-Oncology and Bone Marrow Transplant. His laboratory focuses on immune evasion mechanisms in Adult and Pediatric CNS Malignancies. He was part of the original CD47 disease team as a Senior Scientist at Stanford University.

Yaping Shou
Yaping Shou
Chief Medical Officer
Trillium Therapeutics
Yaping Shou
Chief Medical Officer
Trillium Therapeutics

Dr. Yaping Shou is the Chief Medical Officer of Trillium Therapeutics, a clinical-stage immune-oncology company developing innate immune checkpoint inhibitors. She has close to 20 years of industry experience spanning clinical development and translational medicine, with a strong focus in oncology. She most recently served as Executive Medical Director with Takeda Pharmaceuticals, and prior to joining Takeda, she held several clinical development positions with increasing responsibilities at Novartis Pharmaceuticals and GlaxoSmithKline. She received her MD from Zhejiang University School of Medicine and her PhD in Cellular and Molecular Biology from Drexel University College of Medicine and the University of Pennsylvania. She also conducted postdoctoral studies in the Genetics Branch at the National Cancer Institutes.

Taylor Schreiber
Taylor Schreiber
Chief Scientific Officer
Shattuck Labs
Taylor Schreiber
Chief Scientific Officer
Shattuck Labs

Taylor  co-founded  Shattuck Labs  and currently serves  as Chief Scientific Officer  and is a member of the Board  of Directors. Taylor is the lead  inventor of Shattuck’s ARC technology  platform.

Prior  to Shattuck,  Taylor served as  Chief Scientific Officer  of Heat Biologics, Inc. where  he was a co-inventor of significant  elements of Heat’s ImPACT and ComPACT  technology platforms. He was also the co-inventor  of TNFRSF25 agonist technology developed by Pelican  Therapeutics, where he served as Chairman of the Scientific  Advisory Board. Taylor has numerous publications in the field  of tumor immunology and immunotherapy, spanning the subjects of cancer  vaccines, therapeutic proteins and antibodies, adenosinergic and IDO mediated  immunosuppression and regulatory T cell biology. In 2008, Taylor received the  best overall research award at the National Student Research Forum and in 2011 he  was nominated as a Future Leader in Cancer Research by the American Association for  Cancer Research.

Taylor  received  his M.D. and  Ph.D. degrees from  the Sheila and David  Fuente Program in Cancer  Biology at the University of  Miami Miller School of Medicine.  He received his B.A. in Biology from  Bucknell University.

Taylor Guo
Taylor Guo
Co-Founder & CSO
I-Mab Biopharma
Taylor Guo
Co-Founder & CSO
I-Mab Biopharma

As CSO and a co-founder of I-Mab, Dr. Guo oversees Drug Discovery and Translational Medicine functions. He also leads scientific evaluation of potential business development deals. Prior to I-Mab, he worked on the discovery and development of novel drugs for neuro-inflammatory and neurodegenerative disorders at GlaxoSmithKline R&D for 8 years as leader or co-leader for 3 small molecule and 2 protein drug programs to up to phase I trials. He is particularly keen on developing facile and robust assays in order to drive rapid progression. For his contributions, he received a number of awards including the prestigious First-Time-in-Human award, Exceptional Science Awards twice, Best Team award as Leader (may be omitted).

 

Dr. Guo’s interest in drug research can be traced back to his undergraduate years in US where he got a pain research internship in the Department of Pharmacology in University of Iowa. He later moved on to the Division of Nephrology and the Division of Endocrinology at Harbor-UCLA Medical Center as a research associate. Dr. Guo has a PhD degree in immunology and a MSc degree in medical genetics from Shanghai Jiaotong University School of Medicine. He has published more than 35 papers in scientific journals.

Takashi Matozaki
Takashi Matozaki
Professor, Dean of the Graduate School of Medicine
Kobe University
Takashi Matozaki
Professor, Dean of the Graduate School of Medicine
Kobe University

Professor Matozaki is a pioneer researcher who first discovered SIRPα and has been working for the roles of the CD47-SIRPα system in various cell functions, particularly macrophages and dendritic cells for cancer immunity as well as autoimmunity.

Limin Shang
Limin Shang
Pharmacology Director
LightChain Bioscience
Limin Shang
Pharmacology Director
LightChain Bioscience

After obtaining a PhD in pharmacology from SUNY Buffalo, NY, Limin worked on preclinical disease models for several years at Roswell Park Cancer Institute and Mount Sinai School of Medicine, NY. At Novimmune since 2009, he was involved in the preclinical development of several therapeutic antibody programs in autoimmunity and κλ body bispecific antibody programs in immuno-oncology.

In July 2019, Novimmune has been rebranded as “Light Chain Bioscience – A brand of Novimmune SA, and continues to work on novel bispecific technology and associated programs. As the director of pharmacology at Light Chain Bioscience, Limin is in charge of the pharmacological characterization of all bispecific antibody programs.

Claire Xu
Claire Xu
US Site Head
I-Mab Biopharma
Claire Xu
US Site Head
I-Mab Biopharma

Dr. Claire Xu is the US Site Head of I-Mab Biopharma, a global biotech company exclusively focused on developing novel or highly differentiated biologics in the therapeutic areas of immuno-oncology and autoimmune diseases. She has built I-Mab’s US site at Rockville Maryland to a cross-functional clinical development team within 2 years and led the clinical development programs for all I-Mab global pipelines. Prior Joining I-Mab, she was a clinical pharmacologist focusing on Phase 1 clinical development at Otsuka Pharmaceutical Development & Commercialization for five years. Dr. Xu received her MD from Sun Yat-sen University and her PhD in Clinical Pharmacology from Indiana University School of Medicine.

André Veillette
André Veillette
Professor, Department of Medicine
University of Montreal
André Veillette
Professor, Department of Medicine
University of Montreal

André Veillette is a world-recognized scientist interested in signal transduction mechanisms in the immune system. Over the past two and a half decades, he has identified and characterized numerous intracellular molecules and receptors that play a crucial role in normal immune regulation.

Jane Lamerdin
Jane Lamerdin
Director, R&D
Eurofins DiscoverX
Jane Lamerdin
Director, R&D
Eurofins DiscoverX

Dr. Jane Lamerdin is the Director of R&D at Eurofins DiscoverX where she currently oversees the development of novel cell-based assays and tools to support portfolio expansion as well as client-focused projects. She has nearly 20 years of industry experience developing and prosecuting diverse cell-based assays to support client drug discovery campaigns, and high throughput, molecular and systems biology research. Prior to joining Eurofins DiscoverX, Jane was Executive Director of Research at Odyssey Thera, where she utilized her expertise in cell signaling pathways, oncology and DNA repair to guide the development of a broad panel of high content cell-based assays for compound safety and selectivity screening, which supported programs in major pharma companies as well as the ToxCast program at the EPA.  Jane received her B.S. and Ph.D. in Genetics from the University of California at Davis; she is co-inventor on over 5 patents and has co-authored over 50 peer-reviewed articles.

Anthony Schwartz
Anthony Schwartz
Chief Executive Officer
Morphiex Biotherapeutics
Anthony Schwartz
Chief Executive Officer
Morphiex Biotherapeutics

Anthony Schwartz, Ph.D. is the Chief Executive Officer of Morphiex Biotherapeutics where he is leading efforts to move its SIRPa and thrombospondin-1 inhibitor through early-stage clinical trials. Before Morphiex, Anthony worked with the NIH/NCI to develop novel CD47 therapies for cancer. He’s founded over 10 companies, obtained FDA approval and pushed several drugs through IND studies. Anthony is also a professor at Johns Hopkins University.

Spencer Liang
Spencer Liang
Senior Director, Head of Immuno-Oncology
Alector
Spencer Liang
Senior Director, Head of Immuno-Oncology
Alector
Sebastian Nijman
Sebastian Nijman
Founder and Managing Director
Scenic Biotech
Sebastian Nijman
Founder and Managing Director
Scenic Biotech

Sebastian is a Co-founder and Managing Director of Scenic Biotech, and also holds an Adjunct Group leader and Associate Professor position at the Ludwig Institute for Cancer Research at Oxford University. 

 

Sebastian obtained his PhD from The Netherlands Cancer Institute and was a postdoctoral fellow at the Broad Institute of Harvard and the M.I.T. He was group leader at the Research Center for Molecular Medicine in Vienna from 2007-2014 and is a member of the Young Academy of the Austrian Academy of Sciences. In 2010 he co-founded Haplogen GmbH and was its COO until 2014. At Haplogen, he initiated a partnership with Horizon Discovery, and co-led the subsequent $12Mio acquisition of Haplogen Genomics.

Stephanie Dougan
Stephanie Dougan
Assistant Professor
Dana-Farber Cancer Institute
Stephanie Dougan
Assistant Professor
Dana-Farber Cancer Institute

Stephanie Dougan received her PhD in Immunology from Harvard University. She then performed a postdoctoral fellowship with Hidde Ploegh at Whitehead Institute. Dr. Dougan joined the faculty at Harvard Medical School and Dana-Farber Cancer Institute in 2014, where her lab uses unique preclinical models to study the immune response to pancreatic cancer. She is particularly interested in why pancreatic cancer has been so refractory to immunotherapy, and has been developing new immunotherapies for this devastating disease. Dr. Dougan’s lab uses alpaca-derived antibodies to deliver cytokine-based immunotherapies to tumors, and uses an alpaca antibody against mouse CD47 to study the role of CD47 in syngeneic tumor models. Dr. Dougan is a Pew-Stewart Scholar in Cancer Research, a Bill and Melinda Gates Global Health Innovation Scholar, a Melanoma Research Alliance Young Investigator, and received a Pathway to Leadership Award from the Pancreatic Cancer Action Network and AACR. She is also dedicated to training young scientists, and received a Young Mentor Award from Harvard Medical School in 2019.

Dan Pereira
Dan Pereira
CSO
Arch Oncology
Dan Pereira
CSO
Arch Oncology

Dan Pereira, PhD, is Chief Scientific Officer at Arch Oncology, a privately held, clinical stage  biotechnology company  developing AO-176, a highly differentiated CD47 antibody, and advancing an immuno-oncology focused pipeline.

Prior to joining Arch Oncology, he served as Vice President, Discovery Research at Agensys/Astellas and before Agensys was Site Head and Vice President, Research at Arius/Hoffmann-La Roche Limited. Dr. Pereira began his industry career at ImClone Systems where he was Director, Tumor Biology.

Daniel Maslyar
Daniel Maslyar
VP of Clinical Development for Oncology
Alector
Daniel Maslyar
VP of Clinical Development for Oncology
Alector
Sergio Trombetta
Sergio Trombetta
Senior Principal Scientist, Cancer Immunology & Immune Modulation
Boehringer Ingelheim
Sergio Trombetta
Senior Principal Scientist, Cancer Immunology & Immune Modulation
Boehringer Ingelheim

Sergio Trombetta obtained his PharmD, PhD from the University of Buenos Aires and did postdoctoral research at Yale Medical School. He joined the Cancer immunology and Immune Modulation Program at Boehringer Ingelheim in 2017, where he has been developing novel immune therapies for oncology and inflammatory conditions.

Michael Dougan
Michael Dougan
Assistant Professor, Medicine
Harvard Medical School
Michael Dougan
Assistant Professor, Medicine
Harvard Medical School

Dr. Dougan is currently an Assistant Professor of Medicine at Massachusetts General Hospital and Harvard Medical School and is the Director of the Immunotherapy Mucosal Toxicities Program at Massachusetts General Hospital. He received his MD and PhD from Harvard Medical School. Dr. Dougan’s research focuses on the balance between antitumor responses and immune toxicities.

Tabitha Cooney
Tabitha Cooney
Paediatric Neuro-Oncologist
Dana Farber Cancer Institute
Tabitha Cooney
Paediatric Neuro-Oncologist
Dana Farber Cancer Institute

Dr. Cooney is a pediatric neuro-oncologist at Dana-Farber/Boston Children’s Cancer Center, and co-chair of the international Response Assessment in Pediatric Neuro-Oncology (RAPNO) DIPG committee. Her interests lie in the development and design of early phase pediatric CNS malignancy trials. She currently leads several multi-institutional trials through national and international pediatric oncology consortia.

Timothy Zheng
Timothy Zheng
Executive Director, Immune Modulation
Boehringer Ingelheim
Timothy Zheng
Executive Director, Immune Modulation
Boehringer Ingelheim

Tim Zheng currently is the Executive Director of Immune Modulation at Boehringer Ingelheim. Tim received his PhD degree in Immunology at Yale in 1999, studying the roles of mammalian caspases using gene targeting. Following his training, Tim joined Biogen’s Immunology Research Department and during his 17 year’s tenure at Biogen, he studied extensively the role of cytokine signaling pathways in tissue inflammation and remodeling processes in both physiological and pathological settings, in particular those of the TNF superfamily members. Tim’s work at Biogen led to several IND filings of both biologics (anti-TWEAK & anti-OSMR mAbs) and small molecule drug candidates (Syk and Btk Inhibitors), as well as the successful BLA filing of Daclizumab (anti-CD25) in multiple sclerosis. Tim authored over 60 publications in peer reviewed journals and served on the study sections of both Arthritis Foundation and Scleroderma Research Foundation. Tim joined BI in 2016 to build and lead the Immune Modulation group in the US (Ridgefield, CT) to explore and exploit the full therapeutic potentials of immunomodulatory mechanisms in human diseases.

Zhengyi Wang
Zhengyi Wang
Senior Director of R&D
I-Mab Biopharma
Zhengyi Wang
Senior Director of R&D
I-Mab Biopharma

Dr. Zhengyi Wang is the co-founder and Executive Director of R&D in I-Mab Biopharma. He has taken on a leadership role in the antibody discovery and translational research in the company. Prior to joining I-Mab, Dr Wang worked for GSK R&D China in the early drug discovery targeting the neuro-inflammatory diseases. Dr Wang holds a Ph.D in immunology from the Chinese Academy of Sciences.

Andrew Pincetic
Andrew Pincetic
Staff Scientist, Immuno-Oncology
Alector
Andrew Pincetic
Staff Scientist, Immuno-Oncology
Alector

Andrew Pincetic is a Staff Scientist in the Immuno-Oncology department at Alector in South San Francisco, where he leads a team investigating the role of myeloid cells in oncology and neurodegeneration. His team is responsible for conducting mechanistic in vitro and in vivo studies to identify novel immune-targeted therapeutics. Dr. Pincetic holds a Ph.D. in Immunology from Northwestern University, where he studied innate immune response to viral infection, and he completed his postdoctoral studies in Fc-receptor biology at the Rockefeller University.

Agenda

  • Conference Day 1: Wednesday, November 4th 2020
  • Conference Day 2: Thursday, November 5th 2020
Conference Day 1: Wednesday, November 4th 2020
8.00
Registration, Breakfast & Networking
9.00
Chair’s Opening Remarks & Setting the Scene
  • A look at the day ahead – what will be the key takeaways we should achieve by the end of this summit?
  • How far have we come in the CD47|SIRPα space since last April?

Kipp Weiskopf, Whitehead Fellow, Whitehead Institute

9:10
Keynote Presentation: Fundamental Biology of the CD47|SIRPα Checkpoint

Timo Van Den Berg, Professor of Immunotherapy, Head Department of Blood Cell Research, Sanquin Research, Amsterdam University Medical Center

9:35
Presentation: A Novel MOA-reflective Bioassay for Quantifying Potency of Therapeutics Targeting the SIRPα|CD47 Signaling Axis

Jane Lamerdin, Director, R&D, Eurofins DiscoverX

10:00
Panel Discussion and Open Q&A: What Impact is our Current Level of Understanding of the CD47|SIRPα Checkpoint Having on the Industry?
  • What knowledge do we need to further the development of CD47|SIRP​α​ targeted therapies
  • What are the specific hurdles within research that prevents information about the CD47|SIRP​α​ being discovered?
  • Do we understand sufficiently which immune functions are controlled by CD47-SIRPα and how?
  • What is the fundamental role of SIRP​α ​on tumors?
  • As we move further into human trials, what are we expecting to learn about the fundamental biology of CD47/SIRPa?

Dan Pereira, CSO, Arch Oncology

Michal Caspi Tal, Instructor & Team Lead, Stanford University

Anthony Schwartz, CEO, Morphiex

Timo Van Den Berg, Professor of Immunotherapy, Head Department of Blood Cell Research, Sanquin Research, Amsterdam University Medical Center

10:40
Morning Refreshments and Networking
11:20
Presentation: What Do We Know About the Fundamental Biology Behind Alternative SIRP Homologs and an Overview of OSE Immunotherapeutics’ Approach

Nicolas Poirier, Chief Scientifc Officer, OSE Immunotherapeutics

11:45
Presentation: How Do Macrophages Work In Relation To CD47|SIRPα?
  • We learn more about the fundamental biology behind macrophages and how they interact with CD47.  
  • Why macrophages rather than dendritic/myeloid cells? 
  • What is the role of macrophage polarity as it pertains to promoting phagocytosis following SIRPa/CD47 blockade?

Stephanie Dougan, Assistant Professor, Dana-Farber Cancer Institute

12:10
Panel Discussion and Open Q&A: What Does “Eat Me” Mechanistically Mean for Macrophages In Relation To CD47|SIRPα?
  • How do we activate and how do we increase macrophage activity? 
  • What are the different types of macrophages, does the targeted therapy approach need to change depending on the type of macrophage?
  • Can CD47/SIRPa blockade single handedly influence what macrophages do with the tumor antigens after they are ‘eaten’?
  • What other signals/pathways in macrophages need to be engaged?
  • How do we measure/confirm macrophage phagocytosis in a clinical trial setting? 

Siddhartha Mitra, Assistant Professor, University of Colorado

Sergio Trombetta, Senior Principal Scientist, Cancer Immunology & Immune Modulation, Boehringer Ingelheim

Stephanie Dougan, Assistant Professor, Dana-Farber Cancer Institute

Takashi Matozaki, Professor, Dean of the Graduate School of Medicine, Kobe University

12:50
Lunch and Networking

Combinations in Action

1:50
Presentation: QPCTL - A Druggable Modifier of the CD47/SIRP Therapeutic Axis

Sebastian Nijman, Founder & Managing Director, Scenic Biotech

2:15
Panel Discussion and Open Q&A: Chemotherapy, T-cell Immunotherapy and Radiotherapy - Where do these Fit in Combination with CD47|SIRPα?
  • What do we know so far about combining these targets with CD47|SIRPα both preclinically and clinically?
  • How effectively does radiotherapy work alongside CD47|SIRPα
  • What are the risks of combining these immuno-oncology targets?
  • What are the potential impacts of immunogenic vs non-immunogenic cell killing on CD47|SIRPα compounds, does one route work better than the other? 
  • How predictive/how useful are preclinical models in this space?

Siddhartha Mitra, Assistant Professor, University of Colorado

André Veillette, Professor, Department of Medicine, University of Montreal

Timothy Zheng, Executive Director, Immune Modulation, Boehringer Ingelheim

CD47|SIRPα in the Clinic

2:50
Presentation: Tackling Solid Cancers using a Bispecific Antibody Approach - Light Chain Bioscience
  • A look at the advantages of targeting CD47 with a bispecific antibody approach. 
  • We hear about Mesothelin as a target for solid cancers. 
  • An insight into preclinical data for the CD47 x Mesothelin bispecific antibody.

Limin Shang, Pharmacology Director, LightChain Bioscience

3:15
Afternoon Refreshments and Networking
4:00
ALX148: Designed For Safety To Maximize Efficacy

Jaume Pons, President & CEO, ALX Oncology

4:25
Presentation: TJC4 – A Differentiated CD47 Antibody in Clinical Development

Claire Xu, Head of US Site, I-Mab Biopharma

4:50
Panel Discussion and Open Q&A: What are the Predictive Biomarkers Arising when Targeting CD47|SIRPα Pathways?
  • What are the best biomarker strategies to validate how clinical trials are going?
  • SIRPα/CD47 tumoral expression: is there any correlation with clinical efficacy?
  • Macrophage/T-cell infiltrates: is there any correlation with clinical efficacy?
  • What other biomarkers should be considered in regards to CD47|SIRPα drugs? 
  • What biomarkers are biotech companies using to track macrophages in clinic?

Moderated by:  Nicolas Poirier, CSO, OSE Immunotherapeutics 

Claire Xu, Head of US Site, I-Mab Biopharma

André Veillette, Professor, Department of Medicine,University of Montreal

Spencer Liang, Senior Director, Head of Immuno-Oncology, Alector

Limin Shang, Pharmacology Director, LightChain Bioscience

5:30
Close of Day 1
Download Agenda
Conference Day 2: Thursday, November 5th 2020
9:00
Chair’s Opening Remarks & Setting the Scene
  • What have we learnt so far at CD47|SIRPα 2020? 
  • What can we expect from today?

Siddhartha Mitra, Assistant Professor, University of Colorado

9:10
Presentation: An Insight into Trillium Therapeutics’ Progress and What’s To Come.

Yaping Shou, Chief Medical Officer, Trillium Therapeutics 

9:35
Presentation: Genetic Variations in SIRPa Impact CD47 Interactions.

Michal Caspi Tal, Instructor & Team Lead, Stanford University

Building Clinical Best Practice

10:00
Panel Discussion and Open Q&A: How Can we Manage Toxicity and Improve Clinical Practice?
  • What toxicities have been identified during preclinical & clinical trials? 
  • Are there specific causes for toxicity and how can we negate these? 
  • Are pre-clinical non-human samples posing problems for future clinical trials? 
  • The RACE For Children Act comes into effect in August 2020, how will this affect clinical trials?
  • How else can we build best practices in clinic? 

Tabitha Cooney, Paediatric Neuro-Oncologist, Dana Farber Cancer Institute 

Michael Dougan, Assistant Professor, Medicine, Harvard Medical School

Daniel Masylar, VP of Clinical Development for Oncology, Alector

10:40
Morning Refreshments and Networking

Additional Pathways – What Else Is In The Pipeline?

11:30
Presentation: CD40 Enhances Type I Interferon Responses Downstream of CD47 Blockade to Bridge Innate and Adaptive Immunity

Taylor Schreiber, CSO, Shattuck Labs

11:55
Presentation: AO-176, A Highly Differentiated Clinical Stage Anti-CD47 Antibody.

Dan Pereira, CSO, Arch Oncology

12:20
Presentation: An Insight Into Alector’s Novel Approach to Drive Anti-Tumor Immunity.

Spencer Liang, Senior Director, Head of Immuno-Oncology, Alector

12:45
Lunch

What’s On The Horizon?

2:15
Panel Discussion and Open Q&A: Reflection and Progression - Where are We and What’s Next for CD47|SIRPα?
  • What challenges have we faced and how can we overcome these?
  • Where do we expect to see the most growth in the next year? 
  • Should enhancing mediated-macrophage phagocytosis be a focus going forward? 
  • How is the future work on emerging “don’t eat me signals” going to benefit from our work with CD47/SIRPα?
  • What have been our biggest takeaways from the CD47/SIRPa 2020 Summit

Timothy Zheng, Executive Director, Immune Modulation, Boehringer Ingelheim

Taylor Schreiber, CSO, Shattuck Labs

Sebastian Nijman, Founder & Managing Director, Scenic Biotech

2:55
Chair's Closing Remarks
  • What have been the key learnings from CD47|SIRPα 2020?

Siddhartha Mitra, Assistant Professor, University of Colorado

3:00
Close of CD47|SIRPa 2020
Download Agenda

Partnership

Our attendees tell us that one of the main reasons they attend our summits is to advance partnership discussions and forge new business relationships.  To facilitate this (and help us fund the event) we have a limited number of partnership opportunities available. This means that our partners can be confident that they can have meaningful conversations – and our attendees know that the composition of the audience is just right.

We invite you to get in touch for a no-obligation conversation.  We will share our audience data with you and help you determine whether this summit is the right fit to facilitate your goals.

Contact Us +
Partnership

Register for the Event

For pricing and booking options please click the button to go to the registration page.

Registration